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Abstract
Nipah virus is a broadly tropic and highly pathogenic zoonotic paramyxovirus in the genus Henipavirus whose natural
reservoirs are several species of Pteropus fruit bats. Nipah virus has repeatedly caused outbreaks over the past decade
associated with a severe and often fatal disease in humans and animals. Here, a new ferret model of Nipah virus
pathogenesis is described where both respiratory and neurological disease are present in infected animals. Severe disease
occurs with viral doses as low as 500 TCID50 within 6 to 10 days following infection. The underlying pathology seen in the
ferret closely resembles that seen in Nipah virus infected humans, characterized as a widespread multisystemic vasculitis,
with virus replicating in highly vascular tissues including lung, spleen and brain, with recoverable virus from a variety of
tissues. Using this ferret model a cross-reactive neutralizing human monoclonal antibody, m102.4, targeting the henipavirus
G glycoprotein was evaluated in vivo as a potential therapeutic agent. All ferrets that received m102.4 ten hours following a
high dose oral-nasal Nipah virus challenge were protected from disease while all controls died. This study is the first
successful post-exposure passive antibody therapy for Nipah virus using a human monoclonal antibody.
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Introduction
Nipah virus (NiV) together with Hendra virus (HeV) are closely
related highly pathogenic zoonoses and are the type species within
the paramyxovirus genus Henipavirus.B o t hv i r u s e sc a nc a u s e
significant morbidity and mortality in a variety of vertebrate
species including humans. The henipaviruses are categorized as
zoonotic biosafety level 4 (BSL-4) agents which has limited an
extensive examination of their in vivo pathogenic features and the
development and evaluation of therapeutics or vaccines. NiV and
HeV are select agents of biodefense concern that are classified as
priority pathogens in category C by the National Institute of
Allergy and Infectious Diseases and the Centers for Disease
Control and Prevention, with the potential to cause significant
morbidity and mortality in humans and major economic and
public health impacts (reviewed [1]). Pteropid bats (family
Pteropodidae), commonly known as flying foxes, are the predom-
inate natural reservoirs for both HeV and NiV (reviewed [2])
although evidence of henipavirus infection has now been
reported in a wider range of both frugivorous and insectivorous
bats [3,4].
Since their initial recognition, both viruses have repeatedly re-
emerged. In total, 13 HeV outbreaks have occurred in Australia in
1994, 1999, 2004, and 2006–2009, and have always involved
horses as an intermediate host with some human infections
including four fatalities, the most recent in September 2009
(reviewed [2]) [5,6]. NiV has also repeatedly caused spill-over
events involving hundreds of human cases since 1998 with at least
nine recognized occurrences primarily in Bangladesh and India
since 2001 (reviewed [2]) with the most recent in March 2008 [7].
Several of the more recent NiV outbreaks have had higher rates of
acute respiratory distress syndrome in conjunction with enceph-
alitis, epidemiological findings consistent with multiple rounds of
person-to-person transmission [8], higher case fatality rates
(,75%), and direct transmission of virus from flying foxes to
humans via contaminated food has been demonstrated [9,10].
In addition to their highly pathogenic nature, the henipaviruses
are also distinguished from all other paramyxoviruses by their
unusually broad host tropism. Host cell infection by NiV and HeV
requires two membrane-anchored envelope glycoproteins; the
attachment (G) glycoprotein which binds the viral receptor, and
the fusion (F) glycoprotein which drives virus-host cell membrane
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and neuraminidase activities and the F glycoprotein is a typical
class I fusion glycoprotein (reviewed in [12]). The host cell
membrane anchored proteins, ephrin-B2 and ephrin-B3 ligands,
have been shown to be the receptors employed by the
henipaviruses [13,14,15,16]. There are presently no licensed
therapeutics available to treat infection caused by the henipa-
viruses. Recently, we isolated and extensively characterized a
neutralizing human monoclonal antibody (hmAb), m102.4, which
recognizes the receptor binding domain of the HeV and NiV G
glycoproteins. This hmAb potently neutralized both viruses in vitro
and maintained its biological activity in vivo suggesting its possible
utility as a passive therapeutic modality following henipavirus
infection [17]. Here we report the development and character-
ization of a novel ferret model of acute NiV infection and
associated disease as well as conduct the first henipavirus
therapeutic antibody trial using the hmAb m102.4. Together,
our data demonstrate that NiV-mediated disease in the ferret
closely resembles that seen in humans with the presence of both
respiratory and neurological disease. We further demonstrate that
m102.4 is an effective post-exposure therapeutic representing the
first antiviral drug candidate showing in vivo efficacy in treating
lethal NiV-mediated disease, and it is the first human mAb
therapeutic developed and tested for the treatment of henipavirus
infection.
Results
Nipah virus infection and disease in ferrets
In humans, disease resulting from NiV infection can vary in
intensity from an acute febrile illness or one progressing to severe
central nervous and respiratory disease. Pathological findings show
systemic vasculitis, necrotizing alveolitis and meningoencephalitis
[18,19]. The disease in experimentally infected cats and hamsters
is similar [20,21]; but in hamsters meninoencephalitis is more
prominent, while cats develop an acute respiratory disease [22].
Here, we sought to assess a new ferret model of NiV pathogenesis
where our preliminary observations had confirmed susceptibility
to NiV infection, with development of systemic vasculitis and
involvement of the central nervous and respiratory systems. Ferrets
have emerged as a model for several viral respiratory diseases
including avian influenza [23], severe acute respiratory syndrome
[24]), and morbilliviruses [25], close relatives of henipaviruses
[26]. They offer the combined advantages over either of the
aforementioned laboratory animal species of being relatively small
mammals, while displaying complex behaviors especially in
relation to their handlers that may be used to advantage in
clinical assessments. They are however also sufficiently large to
enable repeated collection of a wide range of clinical samples
throughout the course of an experimental infection, as well as
administration of potential therapies in a manner similar and
consistent with human medicine.
We initiated a NiV minimal infectious dose study (MID50) for
the purpose of determining an appropriate challenge dose for
subsequent work that would reliably productively infect naı ¨ve
ferrets. Doses of 50, 500, 5,000 or 50,000 TCID50 were each
administered to groups of two ferrets oral-nasally; the most likely
route of natural infection. Based on prior experience with NiV
infection in cats [22,27,28] and using similar parameters, we
defined infection endpoints in ferrets for the purpose of humane
euthanasia; these were used as surrogates for lethality. Endpoints
were fever plus signs of rapidly progressing clinical illness including
both generalized (e.g. inappetance, depression) and localizing
(e.g.dyspnea, neurological signs) disease signs. Ferrets that received
50 TCID50 (1–50 and 2–50), and one animal that received 500
TCID50 (3–500) remained well throughout the period of
observation, did not shed detectable virus or viral RNA, did not
seroconvert, and their tissues were normal at post mortem and
histological examination. The remaining ferrets developed fever
(4–7 days post-infection (dpi)) and rapidly progressive clinical
illness (6–8 dpi). Ferrets inoculated with 50,000 TCID50 (7–50000
and 8–50000) were euthanized 6 and 7 dpi, respectively; those
inoculated with 5,000 TCID50 (5–5000 and 6–5000) were
euthanized 8 and 10 dpi, respectively, and one ferret inoculated
with 500 TCID50 (4–500) was euthanized 9 dpi.
Clinical signs in affected ferrets included severe depression,
cough, serous nasal discharge, dyspnea and subcutaneous edema
of the head (8–50000); severe depression, orthopnea, and
expiratory dyspnea (7–50000); severe depression, orthopnea and
cutaneous ecchymoses (6–5000); severe depression, vomiting and
hypothermia (5–5000); and obtunded with tremor and hind limb
paresis (4–500). Gross pathological findings comprised varying
degrees of subcutaneous hemorrhagic edema of the head and
neck, centered upon local lymph nodes in all diseased ferrets; focal
raised pin-head hemorrhagic nodules scattered throughout the
pulmonary parenchyma; and scattered intra-abdominal petechial
hemorrhages. Histopathology of diseased ferrets revealed acute
focal necrotizing alveolitis and pulmonary vasculitis, acute
glomerular necrosis, focal necrosis of the spleen, and severe diffuse
subacute inflammation of the organs and connective tissues of the
head and neck. Less commonly, there was mild focal nonsuppu-
rative meningitis (4–500, 5–5000 and 8–50000), focal cystitis (4–
500), severe acute necrotizing salpingitis (4–500), acute focal
coagulative necrosis of the adrenal cortex (4–500 and 5–5000), and
severe acute thyroiditis (6–5000). Two ferrets demonstrated
neurological signs (4–500, 5–5000) and had nonsuppurative
meningitis. Syncytia were usually present in lesions and often
contained abundant viral antigen (Figure 1). In mildly affected
lymph nodes there was focal mononuclear cell and neutrophilic
inflammation of the capsule, accompanied by a zone of
subcapsular lymphocyte depletion. In more severely affected
lymph nodes, there was severe extensive hemorrhagic and
coagulative necrosis, often resulting in the destruction of the
entire node with antigen staining mainly in syncytia at the living
margin of the necrotic focus (Figure 1). Clinically healthy ferrets
Author Summary
Nipah virus and Hendra virus are closely related and highly
pathogenic zoonoses whose primary natural reservoirs are
several species of Pteropus fruit bats. Both Nipah and
Hendra viruses can cause severe and often fatal disease in
a variety of mammalian hosts, including humans. The
henipaviruses are categorized as biosafety level 4 (BSL-4)
agents, which has limited the development of animal
models and the testing of potential therapeutics and
vaccine countermeasures. We show here a new ferret
model of Nipah virus pathogenesis in which the underly-
ing pathology closely mirrors the illness seen in Nipah
virus-infected humans, including both respiratory and
neurological disease. We also show that m102.4, a cross-
reactive neutralizing human monoclonal antibody that
targets the viral attachment glycoprotein, completely
protected ferrets from disease when given ten hours after
a lethal Nipah virus challenge. This study is the first
successful and viable post-exposure passive antibody
therapy for Nipah virus using a human monoclonal
antibody.
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significant histological lesions were found in any tissues.
Nipah viral loads and tissue tropism
To examine virus dissemination and tissue tropism, NiV N gene
RNA was measured in pharyngeal and rectal swabs, blood
sampled over the course of infection and in a variety of tissues
recovered at necropsy. Among ferrets that developed clinical
disease, NiV RNA was detected in the blood (Figure 2A) at the
time of euthanasia and, in two of these (5–5000, 6–5000), also in
the sample collected two days earlier. One ferret (3–500) that had
remained healthy during the period of observation demonstrated a
low level of viral RNA in blood 21 dpi. Interestingly, this ferret
shared a cage with ferret 4–500, from which viral RNA was
recovered in pharyngeal and rectal swabs 9 dpi suggesting viral
shedding. Viral RNA (albeit some at low level) was detected in
pharyngeal swabs from all ferrets demonstrating clinical disease
(Figure 2A) and in rectal swabs from two of these (Figure 2A).
Notably, NiV RNA was not detected in any tissues from clinically
healthy ferrets. For all other animals with clinical signs, significant
levels of viral RNA were detected in adrenal, kidney, lung,
bronchial lymph node and spleen tissues (Figure 2B). Although at
lower relative levels, NiV RNA was also detected in the bladder,
liver, ovary or testes, uterine horn and in the brain (Figure 2B).
All infected ferrets had NiV RNA in the olfactory lobe of the brain
and ferret 4–500, which showed tremors and hind limb weakness,
had the highest level in the occipital lobe.
Although real-time PCR can help discern virus distribution in
an infected animal, it does not discriminate between infectious and
non-infectious genetic material. For these reasons, virus isolation
was attempted from samples and tissues with NiV RNA relative
expression levels above 10. NiV was recovered from almost all
tissues that had high levels of NiV RNA (Figure 2B, top panel) as
indicated by the (+) above individual data bars. Lungs and
lymphoid tissues were sites of extensive virus replication. Virus was
also isolated from tissues with lower NiV RNA levels, including the
occipital lobe, uterine horn and ovary from ferret 4–500 and the
olfactory lobe from ferret 8–50000 (Figure 2B, bottom panel).
For ferrets where NiV was isolated from brain, histological lesions
included nonsuppurative meningitis.
Antibody m102.4 prevents NiV disease in ferrets
Recently, we described a hmAb, m102.4 which engages the
receptor-binding site of the viral attachment G glycoprotein,
potently neutralizes HeV and NiV in vitro, and retained its
biological activity in vivo [17]. For the evaluation of m102.4
Figure 1. NiV in ferret tissues. Immunohistochemistry was done using a rabbit antiserum against Nipah virus nucleoprotein with haematoxylin
counterstain as previously described [22]. (A) ferret 7–50000, lung tissue with severe acute necrotizing alveolitis and vasculitis. Antigen present in
syncytia (long arrow) and blood vessel wall (short arrow). (B) ferret 4–500, antigen staining in arachnoid membrane of the meninges, with non-
suppurative inflammation. (C) ferret 7–50000, kidney with antigen staining in necrotic glomerular tuft and tubular epithelium; syncytia present in the
epithelium of Bowman’s capsule (arrow). (D) ferret 4–500, inflammation of the peri-tracheal tissues. Antigen present in blood vessel walls, syncytial
cell (arrow). Scale bars=50 mm.
doi:10.1371/journal.ppat.1000642.g001
Passive Human Antibody Therapy for Nipah Virus
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before (pre-) or 10 hrs after (post-) NiV challenge. Each treatment
group contained three ferrets except for the control group (n=2).
At the indicated time, 50 mg of m102.4 was administered via
intravenous catheter. One ferret in the post-challenge group (28-
post) was given m102.4 intraperitoneally due to difficulty in venous
catheterization. Control ferrets (22-con and 25-con) were given
PBS. Ferrets were challenged oral-nasally with a 5,000 TCID50
dose of NiV (ten-fold the MID50 as determined by the dose-
ranging study above). By 6 dpi, ferrets 22-con, 25-con and 23-pre
were febrile (.40uC) and control animals started to demonstrate
signs of clinical illness similar to those seen in the initial MID50
study. By 8 dpi the controls were severely depressed, had
subcutaneous edema of the head and cutaneous hemorrhages
and they were euthanized. By 8 dpi, 24-pre and all ferrets in the
post-group were also febrile with variable levels of depression and
suppression of play activity; a notable sign of abnormal ferret
behavior. At 10 dpi, the temperatures of 23-pre and 27-post had
started to fall, and each demonstrated moderate (23-pre) or mild
(27-post) edema of the throat. 24-pre and 26-post remained febrile
with no localizing signs. By 13 dpi, ferrets 23-pre and 24-pre were
depressed and inappetant with cutaneous ecchymoses; ferret 23-
pre had marked hind limb paresis and generalized tremor and
both animals were euthanized. All other ferrets (three in the post-
and one in the pre-group) were well and free of any disease signs
and remained so until the end of the study (Table 1). Upon study
completion (20 dpi) all surviving animals were euthanized. For the
controls and two ferrets in the pre-challenge group that
succumbed to infection, gross and microscopic pathology revealed
findings similar to those described above in the MID50 study.
However, in ferrets 23-pre and 24-pre the frequency of pinpoint
hemorrhagic lesions observed in the pulmonary parenchyma was
Figure 2. NiV RNA and virus isolation from ferrets post-challenge. Samples were collected in duplicate, RNA was extracted from one
replicate and assayed using Taqman PCR detecting NiV nucleoprotein (N) RNA [22]. Samples were assayed in triplicate. Ct values were analyzed
against a known NiV cDNA control and results are shown as the average relative NiV N gene expression (Y-axis). Error bars represent the standard
deviation. Day of sampling or tissue is indicated (X-axis). Ferret # and NiV dose (TCID50) are indicated (inset). (A) Blood, pharyngeal swabs, rectal
swabs. (B) Vascular and lymphoid tissues (top panel), other tissues (bottom panel); diaph: diaphragmatic; bron-LN: bronchial-lymph node; occ:
occipital; olf: olfactory. For tissue samples with relative NiV N gene expression above 10, virus isolation was performed on duplicate samples. The
presence of infectious virus is indicated by the (+) above individual data bars. Virus isolation was not attempted on blood or swabs.
doi:10.1371/journal.ppat.1000642.g002
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progression in the respiratory tract had been dampened
(Figure 3), consistent with their survival to 13 dpi. Histopatho-
logical findings in controls and in the two diseased pre-challenge
group ferrets were similar to those described in the MID50 study.
However, for ferret 23-pre, NiV antigen was present in ependymal
tissue (Figure 4A) and for ferret 24-pre NiV antigen was present
within neurons and neuropil of the cerebellum (Figure 4B),
further supporting the suggestion that ferrets could be an
appropriate model for NiV-mediated meningoencephalitic disease.
No significant pathological abnormalities were found in any of the
surviving ferrets.
Nipah viral loads and tissue tropism in m102.4 treated
ferrets
Blood, swabs and tissues were tested for the presence of NiV
RNA and results are shown in Figure 5. Ferret 21-pre, the only
animal to survive in the pre-challenge group, had detectable levels
of viral RNA in the blood 3 dpi (Figure 5A) whereas all other
samples were negative. All other ferrets had significant viremia by
8 dpi with the highest levels of NiV RNA in the controls. By
13 dpi, viral RNA levels in ferrets 23-pre and 24-pre were similar
to those found in controls whereas NiV RNA levels had decreased
in ferret 26-post and were undetectable in the other post-challenge
group ferrets. Viral RNA levels in oral swabs were highest among
the controls and pre-challenge group; however, post-challenge
group ferrets shed virus over the course of infection (Figure 5A).
NiV RNA levels in rectal swabs were low except in 23-pre and 24-
pre (Figure 5A). Together these data demonstrated that all
treated ferrets (except 21-pre) had significant amounts of systemic
and mucosal NiV for at least 10 dpi. Controls and the two
diseased pre-group ferrets had similar high levels of viral RNA in
all tissues (Figure 5B). Conversely, 21-pre and all post-challenge
group ferrets had significantly reduced levels of viral RNA
(Figure 5B). Virus isolation was attempted on all samples with
detectable NiV RNA (Figure 5). On day 8 post-infection, NiV
was isolated from the blood of one control animal (22-con), from a
pharyngeal swab from the other control animal (25-con) and from
a rectal swab from ferret 23-pre. All other blood and swab samples
were negative for virus isolation despite the high levels of viral
RNA detected. Virus was isolated from the majority of control
animal tissues and the two diseased pre-group ferret tissues;
whereas, for 21-pre and all post-group ferrets, tissues were
negative for NiV. Together, these data demonstrate that treatment
with m102.4 reduced viral replication and spread, and provided a
significant therapeutic benefit leading to the survival of all infected
animals in the post-challenge group.
In vivo m102.4 concentration
To evaluate whether a correlation between m102.4 concentra-
tion and protection existed, levels of m102.4 in serum were
measured (Figure 6). Coincidently, ferret 21-pre had the highest
levels of serum m102.4 pre-challenge along with the longest-lasting
serum levels (Figure 6A) and was the only animal from this group
Table 1. Clinical scoring and outcome of NiV-infected ferrets from m102.4 efficacy trial.
DPI Ferret Fever Depression Play Activity Grooming Inappetance Additional symptoms Total weight loss
6 22-con ++ xx 2
25-con ++ xx +
23-pre + 2 -- 2
8 22-con ++ xxx x 2 -diarrhea 8.7%
25-con ++ xxx x + -blood in mouth 12.3%
23-pre ++ /2 xx +/2 -shivering
24-pre + 2 -- 2
21-pre 22 -- 2
26-post + 2 x/- - 2
27-post ++ /2 x- 2 -diarrhea
28-post ++ /2 x- 2
10 23-pre ++ /2 x/- x + -sneezing, weeping eye, diarrhea
24-pre ++ x- + -nasal discharge
21-pre 22 -- 2
26-post + 2 x/- - 2
27-post 2 + -- 2 -sneezing
28-post 22 -- 2
13 23-pre ++ x/- - + -diarrhea, crusting nasal discharge,
tremors, hind limb paralysis
16.6%
24-pre ++ xxx - + -diarrhea, crusting nasal discharge 4.7%
21-pre 22 -- 2
26-post 22 -- 2
27-post 22 -- 2
28-post 22 -- 2
DPI: days post infection; (2) no symptom; (+) present; (x) presence of abnormality (x: moderate; xx: substantial; xxx: severe). Bold text indicates animals that required
euthanasia due to NiV-mediated disease. For ferret 28-post, m102.4 was administered intraperitoneally.
doi:10.1371/journal.ppat.1000642.t001
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significantly lower m102.4 concentrations compared to the post-
challenge group (Figure 6B). Importantly, m102.4 concentrations
on day 3 correlated with survival and may indicate the existence of
a critical therapeutic window following virus exposure. By 6 dpi,
m102.4 levels in all animals had dropped and were the lowest
among the post-challenge group. Interestingly, on 6 and 8 dpi, 23-
pre had higher serum m102.4 levels than those in the post-group
and succumbed to disease (13 dpi) whereas 27-post had low levels
of m102.4 on these days and survived infection. Antibody specific
for NiV G was measured in serum post-challenge. NiV-G specific
antibodies were detected in controls by 6 dpi (Figure 7). Ferret
21-pre had high levels of G-specific antibodies 10 dpi which likely
reflected m102.4. For all other ferrets, NiV G-specific antibodies
Figure 4. Immunohistochemistry demonstrating NiV antigen in brain tissue in ferrets treated with m102.4 prior to NiV challenge.
(A) Ferret 23-pre; 13 dpi: viral antigen in ependymal epithelium of the lateral ventricle, associated with focal hemorrhage. (B) Ferret 24-pre; 13 dpi:
single focus of viral antigen in the cerebellum. Scale bar=50 mm.
doi:10.1371/journal.ppat.1000642.g004
Figure 3. Gross pathology of the lung post-mortem in ferrets treated with m102.4 prior to NiV challenge. (A) Ferret 21-pre; 20 days post
infection (dpi): no signs of illness, disease or lesions: healthy ferret lungs. (B) Ferret 23-pre; 13 dpi: delayed disease onset, scattered small pinpoint
lesions. (C) Ferret 24-pre; 13 dpi: delayed disease onset, scattered small pinpoint lesions. (D) NiV-infected control ferret; 8 dpi: typical disease onset,
extensive pinpoint lesions.
doi:10.1371/journal.ppat.1000642.g003
Passive Human Antibody Therapy for Nipah Virus
PLoS Pathogens | www.plospathogens.org 6 October 2009 | Volume 5 | Issue 10 | e1000642Figure 5. Viral loads in ferrets from m102.4 efficacy trial. All samples were collected in duplicate. RNA was extracted from one replicate and
assayed using Taqman PCR assay detecting NiV nucleoprotein (N) RNA. RNA samples were assayed in triplicate. The Ct values were analyzed against a
NiV cDNA control and results are shown as the average relative NiV N gene expression (Y-axis). Error bars represent the standard deviation. Day of
sampling or tissue sample is indicated on the X-axis. Ferret # and treatment group (control (con), pre- or post-challenge) are indicated (inset). (A)
Blood, pharyngeal swabs, rectal swabs. (B) Tissues from diseased ferrets (top panel) or healthy ferrets (bottom panel); diaph: diaphragmatic; bron-LN:
bronchial-lymph node; occ: occipital; olf: olfactory. Virus isolation was attempted from duplicate samples where relative NiV N gene expression levels
were above 10. The presence of infectious virus is indicated by the (+) above individual data bars.
doi:10.1371/journal.ppat.1000642.g005
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post-challenge group. By 13 dpi, NiV-G specific antibody
responses had increased further in all ferrets with the highest
levels found in the 27-post and 28-post ferrets.
Monoclonal antibody resistance and virus strain
specificity
In the present study, we have described m102.4, a potent
neutralizing human monoclonal antibody. Its mechanism of action
involves binding a single epitope within the receptor binding
domain of the henipavirus G glycoprotein and affectively blocking
receptor engagement and virus infection. HeV and NiV cause
acute and often fatal disease in animals and humans and although
virus neutralization escape mutants are unlikely in 7–10 days; we
evaluated whether resistant virus was present in ferrets 23-pre and
24-pre. Virus isolation was repeated on all tissues homogenates in
the presence and absence of m102.4. Virus was isolated from all
samples in the absence of m102.4 as before; however, no virus was
isolated from tissues when m102.4 was present (data not shown).
Together, these data demonstrate that the virus circulating in
ferrets 23-pre and 24-pre at the time of euthanasia was still highly
sensitive to m102.4 and no evidence of escape mutants was found.
In addition, we also examined m102.4 neutralizing activity against
different isolates of NiV and HeV, including, NiV-Malaysia, NiV-
Bangladesh, HeV-1994 and HeV-Redlands. Importantly, m102.4
neutralized all viruses potently: HeV-Redlands was completely
neutralized at 1.25 mg/ml m102.4 and all other isolates were even
more sensitive with complete neutralization occurring at 0.63 mg/
ml m102.4. These data support the potential broad applicability of
m102.4 as a post-exposure therapeutic option for henipavirus-
infected individuals.
Discussion
A new ferret model of NiV infection and pathogenesis has been
developed in the present study. Unlike the cat and hamster
models, the ferret model is unique and exhibits both severe
respiratory and neurological disease, and generalized vasculitis.
NiV-mediated disease in humans has been described as a systemic
endothelial infection accompanied by vasculitis, thrombosis,
ischaemia and necrosis [18]. Histopathological changes in infected
individuals were especially noted in the central nervous system
(CNS) with widespread presence of viral antigen in neurons and
other parenchymal cells in necrotic foci in the CNS and also in
endothelial cells of affected blood vessels. Both vasculitis and
endothelial infection was also seen in most organs examined. In
ferrets, clinical disease included vascular fibrinoid necrosis in
multiple organs, necrotizing alveolitis, syncytia of endothelium and
alveolar epithelium, and necrotizing lymphadenitis. Histopatho-
logical lesions included severe focal necrotizing alveolitis, vascu-
litis, degeneration of glomerular tufts, and focal necrosis in a wide-
range of other tissues. Significant quantities of viral antigen in
blood vessel walls and syncytial cells were frequently present. Viral
antigen was present in neurons and infectious NiV was isolated
from multiple organs including the brain. Several animals also
demonstrated significant neurological disease. A widespread
presence of NiV antigens in neurons and other parenchymal cells
in the CNS was not as extensive as in NiV-infected ferrets as
compared to infected humans, and this could relate to the length
of disease course between these experimental versus natural
infections. We speculate that a more widespread infection in the
CNS would have developed if animals were allowed to succumb to
disease without euthanasia. Overall, NiV-mediated disease in
ferrets has all the hallmarks of NiV-infected humans and
represents a novel relevant animal model.
Recent vaccine studies have demonstrated that henipavirus G-
specific antibodies are critical for protection from disease [22,28].
Evidence of passive protection against NiV, and more recently
HeV, challenge using hamster polyclonal antiserum or murine
mAbs reactive to NiV glycoproteins was provided in the hamster
[29,30,31]. However, in those prior studies, both the challenge
virus and antibodies were administered by intraperitoneal
injection either simultaneously or immediately before or following
challenge. Here we examined a neutralizing fully-human mAb,
with the potential for human use, in a consistently susceptible
animal model where challenge and drug delivery mimicked a
potential real-life scenario.
The hmAb m102.4 is an ideal therapeutic, targeting a critical
functional domain of the G glycoprotein, and is a fully human
IgG. We achieved full protection from NiV-mediated disease in
ferrets who received a single infusion of antibody 10 hrs post-
challenge and protection in one animal treated prior to challenge.
Ferret 21-pre was the only survivor in the pre-group and it had the
highest pre-challenge level of m102.4 and the best antibody
longevity. Uniquely, fever, clinical signs and virus were not
Figure 6. In vivo m102.4 concentrations in ferrets following NiV
challenge. Blood was collected at various time points post-challenge
(X-axis). Serum was collected and frozen at 280uC until the completion
of the study. All sera were c-irradiated to facilitate removal from the
BSL4 laboratory. Sera was diluted and assayed using a NiV G-specific
microsphere assay described previously [17,37]. An m102.4 standard
curve ranging from 500 ng/ml to 0.5 ng/ml and all sera samples were
assayed in duplicate simultaneously. Serum m102.4 concentrations
were extrapolated from the standard curve using non-linear regression
analysis and results are shown as the average concentration. Error bars
represent the standard deviation. Ferret # and treatment group (pre- or
post-challenge) are indicated (inset). (A) m102.4 administered 24 hrs
pre-challenge. (B) m102.4 administered ten hours after post-challenge.
doi:10.1371/journal.ppat.1000642.g006
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extremely low level viremia 3 dpi. These findings suggest that the
combination of an initial high level of antibody and subsequent
longevity may provide protection. For the remaining ferrets,
higher levels of m102.4 on day 3 post-challenge correlated with
protection from disease whereas levels thereafter did not,
potentially highlighting the first 3 days following infection as an
important therapeutic window. On day 3, lower m102.4
concentrations in the pre-group may not have been sufficient to
neutralize all virus, allowing the initiation of infection. In the post-
group the higher concentrations 3 dpi may have sufficiently
neutralized enough virus and/or prevented widespread dissemi-
nation of virus, providing a window for the animal to mount an
effective immune response. In the post-challenge group, the host
immune system may have had an opportunity (10 hrs) to initiate a
primary response before antibody-mediated depletion of virus. In
the pre-challenge group, the antibody-virus complexes most likely
formed almost immediately following challenge and the primary
or innate response may have been dampened. As m102.4 levels
decreased over time and virus replication initiated, the post-
challenge group may have had a more potent secondary response
allowing survival. Indeed, the animals in the pre-challenge group
developed severe disease 7 days after m102.4 levels decreased, a
timeline similar to the disease progression in naive animals.
Whether primary or secondary, the antibody responses in the post-
challenge group appeared earlier (10 dpi) and were more robust.
The survival of all ferrets in the post-challenge group represents
a major step forward towards a viable passive antiviral therapeutic
for treating henipavirus infection. Since m102.4 targets the
receptor-binding domain of G [32] and is a conformation-
dependent antibody, we believe it will maintain efficacy in vivo
during the course of its application in an infected host. Given the
acute nature of henipavirus infection and its receptor specificity,
mutation and escape from m102.4 sensitivity seems unlikely.
Mutations generating m102.4 neutralization escape variant viruses
would likely also acquire defects in receptor binding and fitness.
Our data support this notion as no escape mutants were found in
treated animals that succumbed to disease. Further examination of
m102.4 has confirmed its potent cross-reactive neutralization
activity against the NiV-Malaysia [33], the original HeV-1994
[34], the recent HeV-Redlands [5] and NiV-Bangladesh isolates
[35]. Examination of m102.4 effectiveness in treating animals
exposed to these henipavirus isolates will be important. In future
studies, it will also be critical to increase the number of animals
studied and further explore the therapeutic window post-
challenge. Although 10 hrs is relevant to a known exposure, such
as a laboratory accident, it will be important to define the limits of
the therapeutic window. These data represent the first human
antibody therapy successfully evaluated in vivo for prevention of
lethal henipavirus infection and strongly suggests m102.4 may
prove to be a useful therapeutic used to treat disease in people
caused by these important emerging pathogens.
Materials and Methods
Animal handling and husbandry
Eight adult (1–2 year old) ferrets were used for the NiV minimal
infectious dose study and eight adult ferrets were used for the in
vivo m102.4 efficacy study. All animal studies were endorsed by the
CSIRO, AAHL, Animal Ethics Committee. Ferrets were housed
in pairs in cages in a BSL4 room, fed twice daily with a complete
premium dry food and provided with water ad lib. For
implantation of temperature transponders, NiV challenge, admin-
istration of m102.4 and specimen collection, ferrets were
anaesthetised by intramuscular injection of ketamine (Ketamil,
Troy Laboratories, New South Wales (NSW), AU) and medeto-
midine (Domitor, Pfizer Animal Health, NSW, AU) at dose rates
of approximately 3 mg/kg and 0.03 mg/kg, respectively. For
anesthetic reversal, atimepazole (Antisedan; Novartis, Pendle Hill,
NSW, AU) was given intramuscularly at 50% the dose of
medetomidine. Following challenge, ferrets were assessed daily
and scored out of 10 for a range of clinical observations, including
alertness, playfulness, curiosity, depression, food consumption,
feces production and respiration rate. Real-time monitoring of
Figure 7. Ferret immune responses to NiV G. Blood was collected at various time points post-challenge, as indicated by the X-axis. Serum was
collected and frozen at 280uC until the completion of the study. All sera were c-irradiated to facilitate removal from the BSL-4 laboratory. Ferret sera
were diluted and assayed using the NiV G-specific microsphere assay described previously [37]. Ferret # and corresponding treatment group (control
(con), pre- or post-challenge) are indicated in the legend. Median fluorescence intensities (M.F.I.) are shown on the Y-axis. All assays were performed
in duplicate and the mean M.F.I. is shown. Error bars represent the range of M.F.I. for each sample.
doi:10.1371/journal.ppat.1000642.g007
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implanted subcutaneously [28]. Rectal temperatures and body
weights were recorded on sampling days. Once ferrets were
clinically assessed to be exhibiting signs of severe disease from
which natural recovery was considered unlikely, animals were
euthanized by intravenous injection of sodium pentabarbitone.
Virus isolate and challenge
Ferrets were inoculated oronasally with a low passage NiV
isolate (NiV-Malaysia; EUKK 19817; stock virus titer 4.3610
6
TCID50/ml) [36]. For the MID50 study NiV doses were: 5610
4,
5610
3,5 610
2 and 50 TCID50 (2 ferrets per dose). Based on the
outcome of the MID50 study, for the m102.4 efficacy study all
ferrets were challenged with 5610
3 TCID50.
Preparation and administration of m102.4
The m102.4 hmAb was prepared as previously described [17].
Ferrets were anaesthetised and a 20-g intravenous catheter placed
in the left jugular vein. m102.4 was administered via catheter by
slow infusion over 4 minutes to 6 ferrets (50 mg per ferret); 3
ferrets received antibody 24 hours before NiV challenge and 3
ferrets received antibody 10 hours after challenge. Two ferrets
received PBS, one at 24 hours before challenge and the other at
10 hours after challenge. Catheters were withdrawn and animals
were allowed to recover from the anaesthesia.
Sample collection post-challenge
Blood, oral swabs and rectal swabs were collected 6, 8, 10, 13
and 20 or 21 days post-infection (dpi) for the purpose of assisting in
establishing the infection status of each animal. For the m102.4
study an additional sample was collected during incubation period
(3 dpi). Two aliquots of whole blood were removed from each
sample and serum was collected and aliquoted. One aliquot of
whole blood was added to RiboPure lysis buffer (Ambion Inc.
Austin, TX, USA) containing sodium acetate. Duplicate swabs
were placed in AVL viral lysis buffer (Qiagen Pty Ltd, Clifton Hill,
Victoria, AU) or PBS. After euthanasia, tissue samples were
collected aseptically from lung (apical and diaphragmatic lobes),
brain (olfactory and occipital lobes), heart, bronchial lymph nodes,
spleen, liver, kidney, bladder, and adrenal gland. In females, the
uterine horn and ovaries were collected and in males the testes
were collected. Tissues were either fixed in 10% neutral buffered
formalin, submerged in RLT lysis buffer (Qiagen Pty Ltd)
containing b-mercaptethanol and 1 mm stainless steel beads
(BioSpec Products Inc., Bartlesville, OK, USA) or submerged in
PBS containing 1 mm stainless steel beads. For the MID50 study,
all specimens were placed at 280uC. For the m102.4 efficacy
study, all blood, swab and tissue samples were processed
immediately for RNA extraction and duplicate samples in PBS
were stored at 280uC for virus isolation.
RNA isolation
RNA was purified from blood cells using the RiboPure-Blood
kit (Ambion Inc.), from swabs using the QIAamp viral RNA kit
(Qiagen Pty Ltd) and from tissues using the RNeasy Mini kit
(Qiagen Pty Ltd). Prior to processing, tissues were homogenized
for 2 cycles of 30 sec using a Mini-Bead Beater (Biospec Products
Inc.) and centrifuged to pellet debris.
NiV Taqman PCR assay
Taqman PCR assays were preformed as previously described
[28]. Samples were amplified in a GeneAmp 7500 Sequence
Detection System (Applied Biosystems, Foster City, CA). Ct values
representing NiV nucleocapsid (N) gene expression were analyzed
and data were recorded as relative NiV N gene expression levels.
Virus isolation
Virus isolation was performed as previously described [28] and
only attempted from specimens positive for NiV RNA.
Histopathology and immunohistochemistry
Tissues were processed by routine histological methods and
sections of tissue were stained with hematoxylin and eosin to
examine histopathological changes. Separate sections were stained
by immunohistochemical techniques as previously described [20]
using a rabbit polyclonal antiserum against NiV nucleoprotein.
Measurement of m102.4 and NiV G-specific antibodies in
ferret serum
Multiplexed microsphere assays were performed as previously
described [37]. A LuminexH 100 IS
TM machine and MiraiBio
software (MiraiBio Group, South San Francisco, CA) were utilized
for all assays: Master Plex CT v1.0 for data acquisition and
MasterPlex QT v 2.0 for data analysis. All samples were assayed
simultaneously and concentrations were extrapolated from a
standard curve using non-linear regression analysis (GraphPad
Software, San Diego, CA).
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